1. Home
  2. CRGX vs PKBK Comparison

CRGX vs PKBK Comparison

Compare CRGX & PKBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • PKBK
  • Stock Information
  • Founded
  • CRGX 2021
  • PKBK 1999
  • Country
  • CRGX United States
  • PKBK United States
  • Employees
  • CRGX N/A
  • PKBK N/A
  • Industry
  • CRGX
  • PKBK Major Banks
  • Sector
  • CRGX
  • PKBK Finance
  • Exchange
  • CRGX Nasdaq
  • PKBK Nasdaq
  • Market Cap
  • CRGX 213.5M
  • PKBK 223.5M
  • IPO Year
  • CRGX 2023
  • PKBK N/A
  • Fundamental
  • Price
  • CRGX $4.02
  • PKBK $19.63
  • Analyst Decision
  • CRGX Hold
  • PKBK
  • Analyst Count
  • CRGX 7
  • PKBK 0
  • Target Price
  • CRGX $4.67
  • PKBK N/A
  • AVG Volume (30 Days)
  • CRGX 763.5K
  • PKBK 22.9K
  • Earning Date
  • CRGX 05-16-2025
  • PKBK 04-17-2025
  • Dividend Yield
  • CRGX N/A
  • PKBK 3.66%
  • EPS Growth
  • CRGX N/A
  • PKBK 24.29
  • EPS
  • CRGX N/A
  • PKBK 2.41
  • Revenue
  • CRGX N/A
  • PKBK $64,206,999.00
  • Revenue This Year
  • CRGX $58.18
  • PKBK N/A
  • Revenue Next Year
  • CRGX N/A
  • PKBK N/A
  • P/E Ratio
  • CRGX N/A
  • PKBK $8.17
  • Revenue Growth
  • CRGX N/A
  • PKBK N/A
  • 52 Week Low
  • CRGX $3.00
  • PKBK $15.24
  • 52 Week High
  • CRGX $25.45
  • PKBK $24.29
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 37.02
  • PKBK 63.01
  • Support Level
  • CRGX $3.97
  • PKBK $18.97
  • Resistance Level
  • CRGX $4.66
  • PKBK $19.94
  • Average True Range (ATR)
  • CRGX 0.20
  • PKBK 0.49
  • MACD
  • CRGX -0.05
  • PKBK 0.13
  • Stochastic Oscillator
  • CRGX 6.25
  • PKBK 84.26

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.

About PKBK Parke Bancorp Inc.

Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.

Share on Social Networks: